By Nqobile Dludla JOHANNESBURG (Reuters) -Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it ...

March has officially arrived, which means Spring is finally just around the corner. When it comes to swapping one’s wardrobe ...

We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

In this article, we will take a look into Eli Lilly and Co's (NYSE:LLY) DCF analysis, a reliable and data-driven approach to ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lone Pine Capital. In this article, we are going to take ...

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The ...

More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an ...

People who land in the ER after using hallucinogens are more than twice as likely to die in a handful of years, a new study ...

Tom Lilly has been a staple along sidelines across Eastern Iowa. The only head coach in Xavier girls basketball history is ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

China, India and the US will have the world’s largest populations of adults living with overweight and obesity by 2050, ...